Intellia Therapeutics, Inc. (NASDAQ:NTLA) Shares Purchased by Federated Hermes Inc.

Federated Hermes Inc. boosted its holdings in Intellia Therapeutics, Inc. (NASDAQ:NTLA) by 13.8% in the fourth quarter, HoldingsChannel.com reports. The firm owned 2,016,300 shares of the company’s stock after acquiring an additional 244,722 shares during the period. Federated Hermes Inc.’s holdings in Intellia Therapeutics were worth $61,477,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds have also recently added to or reduced their stakes in NTLA. Barclays PLC boosted its holdings in shares of Intellia Therapeutics by 15.0% during the third quarter. Barclays PLC now owns 256,626 shares of the company’s stock valued at $8,115,000 after acquiring an additional 33,558 shares during the period. ARK Investment Management LLC grew its position in shares of Intellia Therapeutics by 14.7% during the fourth quarter. ARK Investment Management LLC now owns 11,412,449 shares of the company’s stock worth $347,966,000 after acquiring an additional 1,463,820 shares during the last quarter. American Century Companies Inc. grew its position in shares of Intellia Therapeutics by 5.9% during the third quarter. American Century Companies Inc. now owns 267,213 shares of the company’s stock worth $8,449,000 after acquiring an additional 14,863 shares during the last quarter. Raymond James Financial Services Advisors Inc. grew its position in shares of Intellia Therapeutics by 13.3% during the fourth quarter. Raymond James Financial Services Advisors Inc. now owns 36,225 shares of the company’s stock worth $1,104,000 after acquiring an additional 4,255 shares during the last quarter. Finally, Wellington Management Group LLP grew its position in shares of Intellia Therapeutics by 1.4% during the third quarter. Wellington Management Group LLP now owns 2,651,994 shares of the company’s stock worth $83,856,000 after acquiring an additional 36,630 shares during the last quarter. Institutional investors and hedge funds own 88.77% of the company’s stock.

Insider Activity

In other news, EVP James Basta sold 2,297 shares of the firm’s stock in a transaction dated Monday, March 4th. The shares were sold at an average price of $32.99, for a total transaction of $75,778.03. Following the completion of the transaction, the executive vice president now owns 81,571 shares in the company, valued at approximately $2,691,027.29. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Insiders own 3.00% of the company’s stock.

Intellia Therapeutics Trading Up 1.2 %

Shares of NTLA opened at $21.57 on Friday. The firm has a 50-day moving average price of $27.21 and a 200 day moving average price of $27.86. Intellia Therapeutics, Inc. has a 52-week low of $20.78 and a 52-week high of $47.48.

Intellia Therapeutics (NASDAQ:NTLA) last announced its earnings results on Thursday, February 22nd. The company reported ($1.46) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.47) by $0.01. The firm had revenue of ($1.92) million during the quarter, compared to analyst estimates of $15.10 million. Intellia Therapeutics had a negative net margin of 893.34% and a negative return on equity of 43.91%. During the same quarter in the prior year, the firm posted ($1.40) EPS. As a group, sell-side analysts predict that Intellia Therapeutics, Inc. will post -5.58 EPS for the current year.

Analyst Upgrades and Downgrades

Several research firms have recently commented on NTLA. The Goldman Sachs Group lowered shares of Intellia Therapeutics from a “buy” rating to a “neutral” rating and lowered their price target for the stock from $136.00 to $32.00 in a research report on Friday, February 23rd. Wedbush restated a “neutral” rating and set a $29.00 price target on shares of Intellia Therapeutics in a research report on Thursday, February 15th. Canaccord Genuity Group upped their price target on shares of Intellia Therapeutics from $72.00 to $73.00 and gave the stock a “buy” rating in a research report on Friday, February 23rd. Finally, Wolfe Research began coverage on shares of Intellia Therapeutics in a research report on Thursday, February 15th. They set a “peer perform” rating for the company. One analyst has rated the stock with a sell rating, four have given a hold rating and nine have given a buy rating to the stock. According to data from MarketBeat.com, Intellia Therapeutics currently has a consensus rating of “Moderate Buy” and an average price target of $67.00.

About Intellia Therapeutics

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.